Flibanserin- Female Viagra On Steroids

After the blockbuster commercial & physiological success of Viagra by Pfizer here comes another pill that comes to play on big boys’ or rather girls’ ground. Although, the blue pill has some competition from Levitra & Cialis the new pink pill has has an entirely different market. That of the women. The female sex boosting drug has not been christened yet and is currently know by the name of Flibanserin. Tt may hit the market by the name of Girosa or Ectris. Finally someone has chanced upon a clinical method to increase the libido of women. A new pill that promises to increase the sexual desire among women albeit with some side effects. Flibanserin was a chance discovery by Boehringer Ingelheim, a German Pharmaceutical company, which was originally creating an anti-depressant. But after testing found this to be a a poor antidepressant and rather found it to be excellent in another area that of female libido. Same was the case with Viagra which was originally testing a drug to treat high blood pressure and angina (a heart condition). This new drug has not yet been approved by the Food & Drug Administration due to the side effects looming heavier than the benefits. Side effects that where reported by the users where usually low to moderate. These where dizziness, anxiety, fatigue, dry mouth, insomnia, nausea.

During the test one of the questions asked was lacking sexual desire as is common with antidepressants. when they found that Filbaserin worked otherwise in women. Instead of dousing sexual desire it actually inflamed it. the women reported more sexual interest and overall satisfying sexual experiences than before.This led the company to clinically test this new drug for this exact reason. Can it actually increase a woman’s desire for sex?


Flibanserin is now being seen as a new drug for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder (included in the Diagnostic and Statistical Manual of Mental Disorder) which basically means a woman whose is otherwise healthy is a lacking libido, or a lack of sexual desire. It could even be a term made up by Boehringer Ingelheim to invoke a sense of lacking amongst women & lead them to buy Flibanserin. Research shows that 10-20% of women suffer from this HSDD

Flibanserin the Female Viagra

Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman’s sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments. Research by Viagra shows that in the female body it is not the chemicals in the body that stimulates the sex drive rather it is the perception of an object that leads them to sexual craving. The neurological pathway of female sexual desire involves interactions among multiple neurotransmitters, sex hormones and various psychosocial factors.Therefore, it was near impossible for the pharmaceutical company to make Viagra’s counterpart.


The Boehringer Ingelheim Pharmaceutical Company’s test were pretty comprehensive. They administered 2,000 women. Half of whom were put on placebo & the other half were given Flibanserin. The reports showed that those on Flibanserin had a one point increase in sexual desire & pleasing sexual experiences. The new Flibanserin started working after a month’s time with a daily dose on 100mg. MRI tests done on classified HSDD woman showed that there actually is chemical balance disordered within the brain and blood not flowing to those areas as well.

United States Food & Drug Administration approval awaited.

The Medical Language extract:

Flibanserin
3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
Molecular Formula C20H21F3N4O
Molecular Weight 390.40

Flibanserin has preferential affinity for serotonin 5-HT(1A), dopamine D(4k), and serotonin 5-HT(2A) receptors. In vitro and in microiontophoresis, flibanserin behaves as a 5-HT(1A) agonist, a very weak partial agonist on dopamine D(4) receptors, and a 5-HT(2A) antagonist. In vivo flibanserin binds equally to 5-HT(1A) and 5-HT(2A) receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT(2A) receptors in higher proportion than 5-HT(1A) receptors. The effects of flibanserin on adenylyl cyclase are different from those of buspirone and 8-OH-DPAT, two other purported 5-HT(1A) receptor agonists.

Flibanserin reduces neuronal firing rate in cells of the dorsal raphe, hippocampus, and cortex with the CA1 region being the most sensitive in the brain. Flibanserin-induced reduction in firing rate in the cortex seems to be mediated through stimulation of postsynaptic 5-HT(1A) receptors, whereas the reduction of the number of active cells seems to be mediated through dopamine D(4) receptor stimulation. Flibanserin quickly desensitizes somatic 5-HT autoreceptors in the dorsal raphe and enhances tonic activation of postsynaptic 5-HT(1A) receptors in the CA3 region. Flibanserin preferentially reduces synthesis and extracellular levels of 5-HT in the cortex, where it enhances extracellular levels of NE and DA.

Flibanserin displays antidepressant-like activity in most animal models sensitive to antidepressants. Such activity, however, seems qualitatively different from that exerted by other antidepressants. Flibanserin seems to act via direct or indirect stimulation of 5-HT(1A), DA, and opioid receptors in those animal models. Flibanserin does not display consistent effects in animal models of anxiety and seems to exert potential antipsychotic effects. Flibanserin may induce some sedation but does not induce observable toxic effects at pharmacologically relevant doses.

Related Posts

1. Rape-aXe: The Female Condom With Teeth That Bite